Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals

Li, Weidong; He, Mei-Ni; Chen, Qilin; Gong, Heng; Zhang, Li; Zeng, Xian‐Tao

doi:10.1007/s11033-013-2708-y

Cited by 16 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The five SNPs perform a role in the alteration of the transcription of the VEGF gene and also affect the expression of the VEGF gene. Several previous clinical studies have revealed that the five SNPs are associated with the development and prognosis of cancers (18)(19)(20)25). In the present study, it was found that subjects carrying the -634GG genotype possessed a significantly increased risk of osteosarcoma, and this genotype was also associated with a shorter OS time in patients with osteosarcoma.…”

Section: Discussionsupporting

confidence: 65%

“…VEGF is regarded as the most potent stimulatory cytokine for the initiation of tumor angiogenesis and is also an important factor for the development, metastasis, survival and spread of the tumor (24). Previous studies have reported that the expression of VEGF demonstrates an effect on the development and prognosis of several types of cancer (18)(19)(20)25). The VEGF-2578C/A, -1156G/A, +1612G/A, +936C/T and -634G/C SNPs have been previously identified, and all the polymorphisms were found to be located at the promoter region of VEGF.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Liu¹,

Bai²,

Duan³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the association between five common small nucleotide polymorphisms (SNPs) in the VEGF gene and the risk of osteosarcoma. An additional aim was to investigate the role of these five SNPs on the prognosis of osteosarcoma. A total of 186 patients with osteosarcoma and 186 age-and sex-matched healthy controls were enrolled into the present study. A polymerase chain reaction-restriction fragment length polymorphism assay was conducted to determine the incidence of the VEGF-2578 C/A, -1156 G/A, +1612 G/A, +936 C/T and -634 G/C polymorphisms. Conditional logistic regression analyses revealed that individuals carrying the -634 GG genotype possessed a significantly increased risk of osteosarcoma, with an adjusted odds ratio [(95% confidence interval (CI)] of 2.00 (1.07-3.75). In the Cox proportional hazards model, subsequent to adjusting for potential confounding factors, patients with osteosarcoma carrying the -634 GG genotype were found to demonstrate a shorter overall survival time (hazard ratio, 3.10; 95% CI, 1.17-8.38). The VEGF-634 G/C polymorphism may therefore be used as a genetic marker for the prediction of the risk and clinical outcome of osteosarcoma. IntroductionOsteosarcoma is derived from mesenchymal tissues and often occurs in the distal femur, proximal tibia and humeral metaphysis. Osteosarcoma is one of the most common malignant tumors in children and adolescents. It is estimated that the annual incidence of osteosarcoma is 4-5 cases per 1,000,000 individuals worldwide, and osteosarcoma is a leading cause of cancer-associated mortalities in children and young adults (1-3).The development of osteosarcoma is a complex, multistep and multifactorial process in which numerous factors are implicated (4-6). Several studies have been performed to investigate cancer stem cells and the potential of these cells to cause tumors (7,8). The concept that genetic factors are involved in the development of osteosarcoma has led to numerous studies investigating genetic determinants for osteosarcoma in the past decade (10-13).Vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens, and performs an important role in angiogenesis (14,15). The VEGF gene, which consists of eight exons that undergo alternative splicing to form a family of proteins, is located at chromosome 6p21.3. It is well known that the VEGF gene results in several alternatively spliced isoforms, and the regulation of VEGF expression can reveal the difference between normal and tumor tissues. It is estimated that there are >30 types of single nucleotide polymorphism (SNP) in the VEGF gene (16), and several SNPs in the VEGF gene have been reported to affect the expression of the VEGF gene (16). Among these SNPs, five common SNPs in the VEGF gene, consisting of -2578C/A, -1156G/A, +1612G/A, +936C/T and -634G/C, are reported to be associated with VEGF protein synthesis (17). The -2578C/A and -1156G/A SNPs are located at the VEGF promoter region, and the +1612G/A, +936C/T and...

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Liu¹,

Bai²,

Duan³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Many studies have previously investigated the association between TNF-α G-308A polymorphism and MI risk, but have yielded inconsistent results. Meta-analysis is a useful method to combine various single studies to obtain a larger sample size (Bax et al, 2007;Zeng et al, 2015a), and has been widely used in genetic association studies (Leng et al, 2013;Mao et al, 2013;Yan et al, 2014;Suo et al, 2015;Zeng et al, 2015b). In the present study, we performed a metaanalysis to evaluate the association between TNF-α G-308A polymorphism and MI risk.…”

Section: Discussionmentioning

confidence: 99%

Association between TNF-α rs1800629 polymorphism and the risk of myocardial infarction: A meta-analysis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The tumor necrosis factor-alpha (TNF-α) G-308A polymorphism has been suggested to be a susceptibility factor for myocardial infarction (MI). However, differing results from various studies have led to controversial conclusions. Hence, we performed a meta-analysis to evaluate the association between TNF-α G-308A polymorphism and MI. Reported studies published before March 30, 2015 were included and analyzed from the PubMed and Embase databases. Study selection and data extraction were carried out independently by two authors. The odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association between the selected variables using the Comprehensive Meta-Analysis v2.2 software. In total, 12 publications with 13 case-control studies consisting of 6037 cases and 7262 controls However, when subgroup analysis was performed according to the stages of MI, results indicated that there was a significant association between TNF-α G-308A polymorphism and the risk of acute MI. Other subgroup analyses revealed no significant associations. Current evidence suggests that TNF-α G-308A polymorphism may be associated with increased risk for acute MI.

show abstract

“…This encouraged the completion of the present meta-analysis. Meta-analysis is a method for combining relevant global studies to increase the statistical power and resolve the discrepancy issue of genetic association studies (31)(32)(33)(34). In the present meta-analysis, a total of 12 case-control studies involving 2,095 patients and 3,766 control individuals were analyzed to provide a comprehensive assessment of the association between the EGF 61A/G polymorphism and HCC risk.…”

Section: Discussionmentioning

confidence: 99%

Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

Abstract. The association between hepatocellular carcinoma (HCC) and the epidermal growth factor (EGF) 61A/G polymorphism has been analyzed in several studies, but results remain inconsistent. Therefore, the aim of the present study was to quantitatively summarize the association between the EGF 61A/G polymorphism and the risk of HCC. The PubMed and EMBASE databases were searched for studies published prior to May 1, 2014. The overall, subgroup and sensitivity analyses were conducted using Comprehensive Meta-Analysis software, version 2.2. In total, 12 published case-control studies, consisting of 2,095 patients with HCC and 3,766 control individuals, were included in the present study. Meta-analysis of the included studies revealed that EGF 61A/G polymorphism contributed to the risk of HCC under all four genetic models, consisting of the G vs. A (OR, 1.25; 95% CI, 1.11-1.40), GG vs. AA (OR, 1.53; 95% CI, 1.26-1.85), GG vs. AG + AA (OR, 1.34; 95% CI, 1.13-1.58) and GG + AG vs. AA (OR, 1.27; 95% CI, 1.08-1.49) comparisons. Subgroup analysis further suggested that EGF 61A/G polymorphism was associated with the risk of HCC in patients and control individuals with liver disease, based on ethnicity and source of control, respectively. No other significance in residual subgroup analysis was observed. The present meta-analysis suggests that the EGF 61A/G polymorphism is associated with an increased risk of HCC and may be a potential marker for liver disease, such as hepatitis B virus infection, hepatitis C virus infection and liver cirrhosis. IntroductionHepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and develops predominately in individuals with liver cirrhosis (1). Cirrhosis is the strongest known risk factor for HCC, particularly cirrhosis resulting from infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) (2,3). Additionally, heavy alcohol consumption, diabetes, obesity and tobacco use have been considered to contribute to the local burden of HCC (4,5). However, only a small number of people exposed to these risk factors develop HCC, suggesting that other environmental and genetic factors may play a role in HCC development. For this reason, the pathogenesis of HCC has not been fully elucidated.Additionally, numerous clinicians rely on serological α-fetoprotein testing and abdominal ultrasound imaging for HCC screening (6). However, these screening tools demonstrate low sensitivity and specificity (7-9) and the diagnoses of HCC are made late in the course of the disease. Therefore, early identification of molecular markers associated with an increased risk of HCC has been proposed as an alternative strategy for the diagnosis of HCC.Epidermal growth factor (EGF) was first isolated in 1962 (10) and plays a critical role in liver tissue regeneration (11). In previous years, numerous studies have revealed that the EGF signaling pathway with the EGF 61A/G polymorphism (rs4444903), a commonly functional single-nucleotide polymorphism (SNP) in the 5'-untranslated region of the EGF gen...

show abstract

Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals

Cited by 16 publications

References 26 publications

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients

Association between TNF-α rs1800629 polymorphism and the risk of myocardial infarction: A meta-analysis

Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

Contact Info

Product

Resources

About